KLRK1 and gastric cancer: Natural killer Group 2 Member D (NKG2D) is a key receptor for the activation of NK cells, and it has been found that the expression of NKG2D in patients with gastric cancer has been positively associated with improved clinical outcomes, including better overall survival (OS) (38).